Craig Martin, veteran health and life science market strategist has joined the Board of Directors of FCF. Craig is CEO of the strategy and communications firm Feinstein Kean Healthcare (FKH), an Ogilvy company based in Cambridge MA, with offices in other life science, health and technology hubs around the country.
Craig has been an advisor to leading and emerging biotech, pharmaceutical, diagnostic, health IT and other companies and advocacy organizations for nearly three decades, managing businesses, teams and consultancies based in Cambridge, New York, Washington, DC, and Brussels, Belgium. During the past decade in particular, Craig has spent considerable time working with companies and non-profit groups focused in rare disease and oncology. He has also been a speaker and advisor on shifting advocacy models that reflect the new role of patients and their data in biomedical research and development.
“Craig Martin adds a heightened level of expertise to the FCF board. He brings a deep knowledge of the medical research environment and how FCF might best interact with it. Craig also helps FCF to see where we stand in the broader, rare cancer foundation world, and how we can do better at what we do” states Marna Davis, Board Chairman of the FCF. “His respect in the healthcare community and passion for helping rare cancers such as ours will benefit the many patients and families challenged by this disease. We are incredibly honored to have him on board.”
“I’m honored to have the opportunity to help serve the Fibrolamellar Cancer community,” said Craig, “I’ve been really impressed by the incredible progress FCF has made in a few short years – attracting partners like the Broad Institute, Cancer Research Institute, Duke, Harvard, Johns Hopkins, Memorial Sloan Kettering, Rockefeller, Stanford, UCSF, UNC University of Vermont and Yale. FCF’s efforts have given real hope to young adults and families affected by this devastating disease, and have helped create the scientific foundation for breakthrough discoveries that will lead us closer to treatments and a cure.”